ANDREW SETH GREENBERG
Medical Practice in Boston, MA
License number
Pennsylvania MD028859E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Boston, MA 02111
Pennsylvania
Pennsylvania
Personal information
See more information about ANDREW SETH GREENBERG at radaris.comName
Address
Phone
62 Warfield Ave, Hull, MA 02045
400 S Gill St, State College, PA 16801
110 Rachel Rd, Newton Center, MA 02459
17 Sugar Knoll Dr, Devon, PA 19333
260 Beech Hill Rd, Wynnewood, PA 19096
Professional information
Attorney At Law Office Of David Grossack, P.c.
Position:
Attorney at Law Office of David Grossack, P.C.
Location:
Greater Boston Area
Industry:
Law Practice
Work:
Law Office of David Grossack, P.C.
since Jan 2005
-
Attorney
Andrew M. Greenberg, Attorney at Law
Jul 2003 - Dec 2004
-
Attorney
Education:
Boston University School of Law 1998 - 2001
JD James Madison University 1994 - 1998
BA, Political Science Hull High School 1990 - 1994
JD James Madison University 1994 - 1998
BA, Political Science Hull High School 1990 - 1994
Skills:
Business Litigation, Civil Litigation, Appeals, Commercial Litigation, Litigation, Family Law
Interests:
Ice hockey, skiing, history, music, and reading
Director, Obesity And Metabolism At Human Nutriton Research Center At Tufts
Position:
Director, Obesity and Metabolism at Human Nutrition Research Center at Tufts University
Location:
Greater Boston Area
Industry:
Research
Work:
Human Nutrition Research Center at Tufts University
since Jan 1993
-
Director, Obesity and Metabolism
Tufts University
1995 - 2005
-
Director Obesity Metabolsim
Education:
Amherst College 1973 - 1977
BA, Biology
BA, Biology
Skills:
Cell Biology, Molecular Biology, Metabolism
Andrew S Greenberg, Boston MA
Specialties:
Endocrinologist
Address:
750 Washington St, Boston, MA 02111
Education:
New York University, School of Medicine - Doctor of Medicine
National Institutes of Health-Clinical Center - Fellowship - Endocrinology
Hospital of the University of Pennsylvania - Residency - Internal Medicine
National Institutes of Health-Clinical Center - Fellowship - Endocrinology
Hospital of the University of Pennsylvania - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Endocrinology and Metabolism (Internal Medicine)
Dr. Andrew S Greenberg, Boston MA - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
Tufts Medical Center Clinical Nutrition, Endocrinology, Diabetes and Metabolism
800 Washington St SUITE 268, Boston 02111
(617) 556-3144 (Phone), (617) 556-3224 (Fax)
NEW ENGLAND MED CTR
750 Washington St SUITE 268, Boston 02111
(617) 956-5689 (Phone), (617) 636-4719 (Fax)
800 Washington St SUITE 268, Boston 02111
(617) 556-3144 (Phone), (617) 556-3224 (Fax)
NEW ENGLAND MED CTR
750 Washington St SUITE 268, Boston 02111
(617) 956-5689 (Phone), (617) 636-4719 (Fax)
Certifications:
Diabetes, Metabolism & Endocrinology, 1987, Internal Medicine, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
New York University
Graduated: 1981
Hospital Of The University Of Pennsylvania
Natl Inst Hlth
New York University
Graduated: 1981
Hospital Of The University Of Pennsylvania
Natl Inst Hlth
Andrew Greenberg, Boston MA
Work:
Tufts Medical Center
750 Washington St, Boston, MA 02111
750 Washington St, Boston, MA 02111
Methods For Treating And Preventing Insulin Resistance And Related Disorders
US Patent:
2006001, Jan 26, 2006
Filed:
Oct 29, 2004
Appl. No.:
10/977328
Inventors:
Andrew Greenberg - Boston MA, US
International Classification:
A61K 48/00, A61K 31/202, C12Q 1/00
US Classification:
514044000, 514560000, 435004000
Abstract:
The invention provides methods, therapeutics and kits for treating and preventing diseases or conditions associated with excessive lipolysis, in particular TNF-α induced lipolysis, and/or excessive free fatty acid levels. Exemplary conditions include insulin-resistance, diabetes, in particular NIDDM, obesity, glucose intolerance, hyperinsulinemia, polycystic ovary syndrome, and coronary artery disease. In a preferred embodiment, the method includes administering to a subject in need a pharmaceutically effective amount of an inhibitor of the JNK signal transduction pathway and/or an inhibitor of the MAPK/ERK signal transduction pathway.
Methods For Treating And Preventing Insulin Resistance And Related Disorders
US Patent:
2005014, Jul 7, 2005
Filed:
Oct 29, 2004
Appl. No.:
10/977116
Inventors:
Andrew Greenberg - Boston MA, US
International Classification:
A61K048/00, A61K031/60, C12Q001/00
US Classification:
514044000, 514159000, 435004000
Abstract:
The invention provides methods, therapeutics and kits for treating and preventing diseases or conditions associated with excessive lipolysis, in particular TNF-α induced lipolysis, and/or excessive free fatty acid levels. Exemplary conditions include insulin-resistance, diabetes, in particular NIDDM, obesity, glucose intolerance, hyperinsulinemia, polycystic ovary syndrome, and coronary artery disease. In a preferred embodiment, the method includes administering to a subject in need a pharmaceutically effective amount of an inhibitor of the JNK signal transduction pathway and/or an inhibitor of the MAPK/ERK signal transduction pathway.
Methods For Treating And Preventing Insulin Resistance And Related Disorders
US Patent:
6897019, May 24, 2005
Filed:
Oct 17, 2000
Appl. No.:
09/690647
Inventors:
Andrew S. Greenberg - Boston MA, US
International Classification:
C12Q001/68, G01N033/53, C07K005/00, C07K014/00, C07K016/00
US Classification:
435 6, 435 71, 530300, 530350, 5303871, 536 231, 536 245
Abstract:
The invention provides methods, therapeutics and kits for treating and preventing diseases or conditions associated with excessive lipolysis, in particular TNF-α induced lipolysis, and/or excessive free fatty acid levels. Exemplary conditions include insulin-resistance, diabetes, in particular NIDDM, obesity, glucose intolerance, hyperinsulinemia, polycystic ovary syndrome, and coronary artery disease. In a preferred embodiment, the method includes administering to a subject in need a pharmaceutically effective amount of an inhibitor of the JNK signal transduction pathway and/or an inhibitor of the MAPK/ERK signal transduction pathway.